Transcriptome and Proteome Analyses of TNFAIP8 Knockdown Cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression

  • Timothy F. Day
  • Rajshree R. Mewani
  • Joshua Starr
  • Xin Li
  • Debyani Chakravarty
  • Habtom Ressom
  • Xiaojun Zou
  • Ofer Eidelman
  • Harvey B. Pollard
  • Meera Srivastava
  • Usha N. KasidEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1513)


Tumor necrosis factor-α-inducible protein 8 (TNFAIP8) is the first discovered oncogenic and an anti-apoptotic member of a conserved TNFAIP8 or TIPE family of proteins. TNFAIP8 mRNA is induced by NF-kB, and overexpression of TNFAIP8 has been correlated with poor prognosis in many cancers. Downregulation of TNFAIP8 expression has been associated with decreased pulmonary colonization of human tumor cells, and enhanced sensitivities of tumor xenografts to radiation and docetaxel. Here we have investigated the effects of depletion of TNFAIP8 on the mRNA, microRNA and protein expression profiles in prostate and breast cancers and melanoma. Depending on the tumor cell type, knockdown of TNFAIP8 was found to be associated with increased mRNA expression of several antiproliferative and apoptotic genes (e.g., IL-24, FAT3, LPHN2, EPHA3) and fatty acid oxidation gene ACADL, and decreased mRNA levels of oncogenes (e.g., NFAT5, MALAT1, MET, FOXA1, KRAS, S100P, OSTF1) and glutamate transporter gene SLC1A1. TNFAIP8 knockdown cells also exhibited decreased expression of multiple onco-proteins (e.g., PIK3CA, SRC, EGFR, IL5, ABL1, GAP43), and increased expression of the orphan nuclear receptor NR4A1 and alpha 1 adaptin subunit of the adaptor-related protein complex 2 AP2 critical to clathrin-mediated endocytosis. TNFAIP8-centric molecules were found to be predominately implicated in the hypoxia-inducible factor-1α (HIF-1α) signaling pathway, and cancer and development signaling networks. Thus TNFAIP8 seems to regulate the cell survival and cancer progression processes in a multifaceted manner. Future validation of the molecules identified in this study is likely to lead to new subset of molecules and functional determinants of cancer cell survival and progression.

Key words

TNFAIP8 shRNA and siRNA RNA and microRNA arrays Antibody arrays Cell survival and proliferation Invasion and metastasis Cancer systems biology 



Timothy F. Day, Rajshree R. Mewani, and Joshua Starr contributed equally to this work. This work was supported by grants from the National Institutes of Health (CA68322, CA74175) and Department of Defense (PC074171). TFD was supported, in part, by predoctoral fellowship award from the Department of Defense (W81XWH-10-1-0107). LM2-4175 cells were a gift from Dr. Joan Massagué. Portions of the work presented in this chapter were carried out by TFD and DC toward their Ph.D. dissertations. UNK is a coinventor on patent application, “Anti-apoptotic gene SCC-S2 and diagnostic and therapeutic uses thereof,” (US 12/858,360). Several cell lines were obtained from the Tissue Culture Shared Resource of the Georgetown Lombardi Comprehensive Cancer Center. The RNA array and microRNA array studies were performed using the Genomics and Epigenomics Shared Resource of the Georgetown Lombardi Comprehensive Cancer Center. All shared resources were supported by the NIH Grant P30-CA51008.


  1. 1.
    Patel S, Wang FH, Whiteside TL, Kasid U (1997) Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol 33:197–203CrossRefPubMedGoogle Scholar
  2. 2.
    Kumar D, Whiteside TL, Kasid U (2000) Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin- 1beta-converting enzyme-inhibitory protein. J Biol Chem 275:2973–2978CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang Z, Liang X, Gao L et al (2015) TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells. Oncogene 34:2566–2574CrossRefPubMedGoogle Scholar
  4. 4.
    Sun H, Gong S, Carmody RJ et al (2008) TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133:415–426CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gus-Brautbar Y, Johnson D, Zhang L et al (2012) The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell 45:610–618CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fayngerts SA, Wu J, Oxley CL et al (2014) TIPE3 is the transfer protein of lipid second messengers that promote cancer. Cancer Cell 26:465–478CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lou Y, Liu S (2011) The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. Mol Immunol 49:4–7CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang X, Wang J, Fan C et al (2009) Crystal structure of TIPE2 provides insights into immune homeostasis. Nat Struct Mol Biol 16:89–90CrossRefPubMedGoogle Scholar
  9. 9.
    Horrevoets AJ, Fontijn RD, van Zonneveld AJ et al (1999) Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood 93:3418–3431PubMedGoogle Scholar
  10. 10.
    You Z, Ouyang H, Lopatin D et al (2001) Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem 276:26398–26404CrossRefPubMedGoogle Scholar
  11. 11.
    Kumar D, Gokhale P, Broustas C et al (2004) Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene 23:612–616CrossRefPubMedGoogle Scholar
  12. 12.
    Zhang C, Chakravarty D, Sakabe I et al (2006) Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. Mol Ther 13:947–955CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang C, Kallakury BV, Ross JS et al (2013) The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. Int J Cancer 133:31–42CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Day TF (2015) Effects of TNFAIP8 knockdown on EGFR and IGF-1R signaling and cytotoxicities of targeted drugs in non-small cell lung cancer cells. Ph.D. Dissertation submitted to the Faculty of the Graduate School of Arts and Sciences of Georgetown UniversityGoogle Scholar
  15. 15.
    Zhang LJ, Liu X, Gafken PR et al (2009) A chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor alpha-induced protein 8 (TNFAIP8). J Biol Chem 284:6156–6168CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wang Y, Hayakawa J, Long F et al (2005) “Promoter array” studies identify cohorts of genes directly regulated by methylation, copy number change, or transcription factor binding in human cancer cells. Ann N Y Acad Sci 1058:162–185CrossRefPubMedGoogle Scholar
  17. 17.
    Chakravarty D (2007) Role of SCC-S2 in breast cancer cell proliferation and invasion. Ph.D. Dissertation submitted to the Faculty of the Graduate School of Arts and Sciences of Georgetown UniversityGoogle Scholar
  18. 18.
    Dong QZ, Zhao Y, Liu Y et al (2010) Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Sci 101:1562–1569CrossRefPubMedGoogle Scholar
  19. 19.
    Liu K, Qin CK, Wang ZY et al (2012) Expression of tumor necrosis factor-alpha-induced protein 8 in pancreas tissues and its correlation with epithelial growth factor receptor levels. Asian Pac J Cancer Prev 13:847–850CrossRefPubMedGoogle Scholar
  20. 20.
    Duan D, Zhu YQ, Guan LL et al (2014) Upregulation of SCC-S2 in immune cells and tumor tissues of papillary thyroid carcinoma. Tumour Biol 35:4331–4337CrossRefPubMedGoogle Scholar
  21. 21.
    Eisele L, Klein-Hitpass L, Chatzimanolis N et al (2007) Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol 117:8–15CrossRefPubMedGoogle Scholar
  22. 22.
    Laliberté B, Wilson AM, Nafisi H et al (2010) TNFAIP8: a new effector for Galpha(i) coupling to reduce cell death and induce cell transformation. J Cell Physiol 225:865–874CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Srivastava M, Eidelman O, Jozwik C et al (2006) Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol Genet Metab 87:303–310CrossRefPubMedGoogle Scholar
  24. 24.
    Jozwik CE, Pollard HB, Srivastava M et al (2012) Antibody microarrays: analysis of cystic fibrosis. Methods Mol Biol 23:179–200CrossRefGoogle Scholar
  25. 25.
    Huang D, Li T, Li X et al (2014) HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep 8:1930–1942CrossRefPubMedGoogle Scholar
  26. 26.
    Vinciguerra M, Sgroi A, Veyrat-Durebex C et al (2009) Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 upregulation in hepatocytes. Hepatology 49:1176–1184CrossRefPubMedGoogle Scholar
  27. 27.
    Hu H, Takano N, Xiang L et al (2014) Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget 5:8853–8868CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Liu ZG, Smith SW, McLaughlin KA et al (1994) Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 367:281–284CrossRefPubMedGoogle Scholar
  29. 29.
    Lin B, Kolluri SK, Lin F et al (2004) Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116:527–540CrossRefPubMedGoogle Scholar
  30. 30.
    Mullican SE, Zhang S, Konopleva M et al (2007) Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 13:730–735CrossRefPubMedGoogle Scholar
  31. 31.
    Zhou F, Drabsch Y, Dekker TJA et al (2014) Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signaling. Nat Commun 5:3388. doi: 10.1038/ncomms4388 PubMedGoogle Scholar
  32. 32.
    Wenzl K, Troppan K, Neumeister P, Deutsch AJ (2015) The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms. Curr Drug Targets 16:38–46CrossRefPubMedGoogle Scholar
  33. 33.
    Hanna RN, Cekic C, Sag D et al (2015) Patrolling monocytes control tumor metastasis to the lung. Science 350:985–990CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Höning S, Ricotta D, Krauss M et al (2005) Phosphatidylinositol-(4,5)-bisphosphate regulates sorting signal recognition by the clathrin-associated adaptor complex AP2. Mol Cell 18:519–531CrossRefPubMedGoogle Scholar
  35. 35.
    Traub LM (2009) Tickets to ride: selecting cargo for clathrin-regulated internalization. Nat Rev Mol Cell Biol 10:583–596CrossRefPubMedGoogle Scholar
  36. 36.
    McMahon HT, Boucrot E (2011) Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12:517–533CrossRefPubMedGoogle Scholar
  37. 37.
    Kelly BT, Graham SC, Liska N et al (2014) AP2 controls clathrin polymerization with a membrane-activated switch. Science 345:459–463CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Tong J, Taylor P, Moran MF (2014) Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress. Mol Cell Proteomics 13:1644–1658CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Shevde LA, Samant RS, Paik JC et al (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23:123–133CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Timothy F. Day
    • 1
  • Rajshree R. Mewani
    • 1
  • Joshua Starr
    • 2
  • Xin Li
    • 1
  • Debyani Chakravarty
    • 1
  • Habtom Ressom
    • 1
  • Xiaojun Zou
    • 1
  • Ofer Eidelman
    • 2
  • Harvey B. Pollard
    • 2
  • Meera Srivastava
    • 2
  • Usha N. Kasid
    • 1
    Email author
  1. 1.Georgetown-Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashingtonUSA
  2. 2.Department of Anatomy, Physiology and Genetics, Institute for Molecular Medicine, Center for Medical ProteomicsUniformed Services University School of MedicineBethesdaUSA

Personalised recommendations